文献速递肝病消化内镜

内镜下胃折叠术对非酒精性脂肪性肝病肝纤维化的消退作用

Regression of Hepatic Fibrosis After Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2022-12-23

本研究为前瞻性收集登记资料的回顾性分析,纳入45例肥胖合并非酒精性脂肪性肝病(NAFLD)且临床显著肝纤维化(≥F2)并接受内镜下胃折叠术的患者,评估术后肝纤维化无创指标变化。术后6-12个月,肝纤维化复合评分和影像学纤维化标志物均显著下降,肝酶、胰岛素抵抗、糖化血红蛋白亦显著降低,12个月时总体重减轻15.5%±7.9%。

要点

  • 内镜下胃折叠术可显著降低NAFLD合并≥F2纤维化患者的肝纤维化无创指标。
  • 术后6-12个月肝酶(ALT、AST)和胰岛素抵抗、糖化血红蛋白均显著下降。
  • 12个月时总体重减轻15.5%±7.9%,63%患者达到至少10%的总体重减轻。

核心结论

  • 内镜下胃折叠术似乎能有效治疗NAFLD,即使对肝硬化患者也能显著降低肝纤维化的无创指标。

研究设计与样本

  • 前瞻性收集登记资料的回顾性分析,纳入45例肥胖合并NAFLD且临床显著肝纤维化(≥F2)并接受内镜下胃折叠术的患者。
  • 使用商用平台在胃体放置全层折叠钉以减少胃容量。

主要发现

  • 45例患者年龄51±13岁,体重指数40.7±6.9 kg/m²,所有患者均成功完成内镜下胃折叠术。
  • 6-12个月时丙氨酸氨基转移酶从49.7±36.8 U/L降至24.2±12.0 U/L(P<0.0001),天冬氨酸氨基转移酶从39.1±24.1 U/L降至24.1±10.0 U/L(P<0.0001)。
  • NAFLD纤维化评分从0.48±1.51降至-1.18±1.56(P<0.0001),纤维化-4指数从1.4±1.2降至1.2±0.7(P=0.03)。
  • 振动控制瞬时弹性成像从13.9±7.5 kPa降至8.9±4.8 kPa(P<0.0001),Agile 3+从0.53±0.28降至0.37±0.28(P=0.001)。
  • 受控衰减参数、胰岛素抵抗稳态模型评估和糖化血红蛋白均显著降低(所有P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fibrosis stage is the strongest predictor of mortality in patients with nonalcoholic fatty liver disease (NAFLD). There is currently no approved therapy that specifically targets fibrosis. This study aims to assess the effect of endoscopic gastric plication on hepatic fibrosis in patients with underlying NAFLD. METHODS: This is a retrospective analysis of prospectively collected registry of patients with obesity and NAFLD with clinically significant hepatic fibrosis (≥F2) who underwent endoscopic gastric plication. Full-thickness plications were placed in the gastric body using a commercially available platform to reduce the gastric volume. The primary outcome included various noninvasive tests (NITs) of hepatic fibrosis based on clinical chemistry and/or imaging. The secondary outcomes included NITs of hepatic steatosis, other metabolic outcomes, including hemoglobin A1c, insulin resistance, and total weight loss (TWL), and adverse events. RESULTS: Forty-five patients (age 51 ± 13 years and body mass index 40.7 ± 6.9 kg/m 2 ) were included. All patients underwent endoscopic gastric plication successfully. At 6-12 months, there were significant reductions in biochemistries (alanine aminotransferase: 49.7 ± 36.8 U/L to 24.2 ± 12.0 U/L [ P < 0.0001], aspartate aminotransferase: 39.1 ± 24.1 U/L to 24.1 ± 10.0 U/L [ P < 0.0001]), composite fibrosis score (NAFLD fibrosis score: 0.48 ± 1.51 to -1.18 ± 1.56 [ P < 0.0001], fibrosis-4 index: 1.4 ± 1.2 to 1.2 ± 0.7 [ P = 0.03]), and imaging-based markers of fibrosis (vibration-controlled transient elastography: 13.9 ± 7.5 kPa to 8.9 ± 4.8 kPa ( P < 0.0001) and Agile 3+: 0.53 ± 0.28 to 0.37 ± 0.28 [ P = 0.001]). There were significant reductions in controlled attenuation parameter, Homeostatic Model Assessment for Insulin Resistance, and hemoglobin A1c ( P < 0.05 for all). At 12 months, patients experienced 15.5% ± 7.9% TWL, with 63% reaching at least 10% TWL. DISCUSSION: Endoscopic gastric plication seems effective at treating NAFLD, with significant reduction in NITs of hepatic fibrosis even in patients with cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jirapinyo P, Zucker SD, Thompson CC, et al. Regression of Hepatic Fibrosis After Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022. PMID: 36597405. doi:10.14309/ajg.0000000000002087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。